enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Moderate Buy” by Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $23.2857.

A number of equities research analysts recently commented on ENGN shares. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price target (up from $30.00) on shares of enGene in a report on Wednesday, November 12th. Morgan Stanley boosted their target price on enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, November 12th. UBS Group increased their price target on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. Raymond James Financial raised enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective for the company in a report on Tuesday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of enGene in a report on Wednesday, December 3rd.

enGene Price Performance

ENGN opened at $10.11 on Friday. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $12.25. The firm has a 50-day moving average of $9.57 and a 200 day moving average of $7.84. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market cap of $677.27 million, a P/E ratio of -4.41 and a beta of -0.29.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, research analysts expect that enGene will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Cresset Asset Management LLC bought a new stake in enGene during the 2nd quarter valued at $36,000. Affinity Asset Advisors LLC bought a new position in shares of enGene in the second quarter worth $280,000. Paloma Partners Management Co purchased a new position in shares of enGene in the second quarter valued at $38,000. PFS Partners LLC bought a new stake in shares of enGene during the 3rd quarter valued at $61,000. Finally, Raymond James Financial Inc. lifted its holdings in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.